Psychoplastogens

Delix Therapeutics, a neuroscience company developing novel neuroplasticity-promoting therapeutics for psychiatric and neurological conditions, received regulatory approval and is set to commence recruitment for a Phase 1 clinical trial on its non-hallucinogenic psychoplastogen lead drug candidate...

Delix Therapeutics recently published findings from a study about the mechanism that causes psychoplastogens and serotonin to activate the 5-HT2A receptor in different ways.  The paper, developed in collaboration with researchers at UC-Davis, offers unprecedented insight into the long-standing...

Delix Nabs 2 New Partners Neuroscience company Delix Therapeutics is partnering with Sweden-based Cellectricon and New York-based Expressive Neuroscience. The goal is to expedite Delix's drug development pipeline. Delix's compounds consist of small molecules capable of rapidly inducing...

A new study published in the peer-review journal Cell looks at a novel compound capable of providing some of the therapeutic properties of psychedelics without hallucinations. The paper, co-authored by Delix Therapeutics co-founder and chief scientific officer David Olson, Ph.D.,...